This site is intended for US healthcare professionals.

Safety and tolerability profile

Safety and tolerability profile

Adverse reactions in ≥15% of patients1

Bar chart comparing adverse reactions (≥15% of patients) between FOTIVDA and sorafenib, showing all grades and grades 3 or 4 percentages.

The most common grade 3 or 4 laboratory abnormalities (≥5%) were sodium decreased, lipase increased, phosphate decreased, and lymphocytes decreased.1

*Includes hypertension, blood pressure increased, hypertensive crisis.

Includes hematuria, epistaxis, hemoptysis, hematoma, rectal hemorrhage, vaginal hemorrhage, contusion, gastrointestinal hemorrhage, hematochezia, intraocular hematoma, melena, metrorrhagia, pulmonary hemorrhage, subdural hematoma, gingival bleeding, hematemesis, hemorrhage intracranial, hemorrhoidal hemorrhage, splinter hemorrhages.

Includes diarrhea and frequent bowel movements.

§Includes hypothyroidism, blood thyroid stimulating hormone increased, tri-iodothyronine decreased tri-iodothyronine free decreased.

Includes dermatitis, dermatitis acneiform, dermatitis contact, drug eruption, eczema, eczema nummular, erythema, erythema multiforme, photosensitivity reaction, pruritus, psoriasis, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash morbilliform, rash pruritic, seborrheic dermatitis, skin exfoliation, skin irritation, skin lesion, swelling face, toxic skin eruption, urticaria.

Dr. Barata goes over the AE and tolerability profile of FOTIVDA, including how AE management influences treatment selection.

The majority of patients stayed on treatment.

See results from the pivotal trial.

Reach out to an AVEO Oncology Account Manager.

AE=adverse event; PPE=palmar-plantar erythrodysesthesia syndrome.

Reference: 1. FOTIVDA (tivozanib) [package insert]. Boston, MA: AVEO Pharmaceuticals, Inc, August 2024.